Zynerba Pharmaceuticals Stock News

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc's results for the fourth quarter and full year reveal ample cash on hand, giving the company scope to run pivotal trials of its flagship product Zygel (ZYN00

Zynerba Pharmaceuticals (ZYNE) said the European Commission granted orphan drug designation to cannabidiol, the active ingredient in its transdermal gel Zygel, for the treatment of…

Provides 10-year market exclusivity in EU upon regulatory approval Devon, PA, February 28, 2022 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Commission (EC) has granted orphan drug designation to cannabidiol, the active ingredient in its transdermal gel, […]

Provides 10-year market exclusivity in EU upon regulatory approval Provides 10-year market exclusivity in EU upon regulatory approval

Provides 10-year market exclusivity in EU upon regulatory approval Provides 10-year market exclusivity in EU upon regulatory approval

Manufacturer of transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE ), completed enrollment for the 14-week Phase 2 INSPIRE trial of Zygel (Transdermal CBD Gel) in the treatment of behavioral symptoms of 22q11.2 deletion syndrome in children and adolescents. The company expects top-line data from this trial mid-year 2022. “The completion of enrollment in our INSPIRE trial is an important step forward in advancing Zygel as a potential new treatment option for patients suffering from 22q,” stated Armando Anido , chairman and CEO of Zynerba. “Pending results from the INSPIRE trial and subsequent discussion with the FDA on the regulatory path forward, we plan to advance … Full story available on Benzinga.com

Topline data from Phase 2 INSPIRE trial expected mid-year 2022 Topline data from Phase 2 INSPIRE trial expected mid-year 2022

Cresco Labs Taps Megan Kulick To Serve As VP Of Investor Relations Cresco Labs (OTC: CRLBF ) appointed Megan Kulick to the role of senior vice president of investor relations. Kulick has over 20 years of experience in investor relations, equity research, and portfolio management at bulge bracket US banks and cannabis multi-state operators. Most recently, she led investor relations for AYR Wellness Inc (OTCQX: AYRWF ) . Prior to that, Kulick held several senior positions, including the role of senior vice president at PIMCO, director at Merrill Lynch and VP at JPMorgan Chase. "Megan''s experience in the cannabis industry paired with a long and successful career at some of the most prestigious banks and investment managers makes her the perfect fit as the industry evolves and begins to attract more institutional capital," Dennis Olis, Cresco Labs'' CFO said. Botanacor Laboratories & Agricor Laboratories Welcome Richard Strong As Digital Officer & SVP Of Information Technology Agricor Laboratories and Botanacor Laboratories jointly announced that Richard Strong has joined Agricor and Botanacor as digital officer and senior vice president of information technology.

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE ) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as chief legal officer and corporate secretary. He will assume the duties of Suzanne Hanlon who will retire from her position at the end of February 2022. "We are excited to have Al join our senior leadership team,” Armando Anido, chairman and CEO of Zynerba , said. “He … Full story available on Benzinga.com

DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rar

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has announced the appointment of Albert P Parker as the company's new chief legal officer and corporate secretary.  Parker, an accomplished industry executiv

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as chief legal o

DEVON, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will virtually present a company overview during the 11 th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 a.m. ET.

WASHINGTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Cannabidiol (CBD) Market finds that increasing awareness of cannabidiol''s therapeutic benefits is expediting market growth. Primarily driven by increasing demand for cannabidiol (CBD) for health and wellness purposes is high, the total Global Cannabidiol (CBD) Market is estimated to reach USD 47.22 Billion by 2028, up from USD 4.9 Billion in 2021, at a compound annual growth rate (CAGR) of 21.3%. Furthermore, rising acceptance and use of CBD products due to government approvals to augment the growth of the Global Cannabidiol (CBD) Market, states Vantage Market Research, in a report, titled " Cannabidiol (CBD) Market by Source (Hemp, Marijuana), by Distribution Channel (Online, Offline), by End-Use (Medical, Personal Use, Pharmaceuticals, Wellness), by Region (North America, Latin America, Europe, Asia Pacific) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)". Click Here To Access The Free Sample Report @ https://www.vantagemarketresearch.com/cannabidiol-cbd-market-1252/request-sample (The Free Sample Of This Report Is Readily Available On Request).

Zynerba Pharmaceuticals Inc (ZYNE) shares closed 1.2% lower than its previous 52 week low, giving the company a market cap of $108M. The stock is currently down 8.7% year-to-date, down 23.8% over the past 12 months, and down 86.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 90.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1504.9% The company's stock price performance over the past 12 months lags the peer average by 48.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.